Cancer Progression and Advances in Therapeutics

Anaya Patel

5th September 2024

Introduction:

Cancer represents a significant global health challenge, being the second leading cause of death worldwide. In 2020, it accounted for nearly 10 million deaths, highlighting its pervasive impact on human health and well-being [1, 3]. The burden of cancer is projected to escalate, with estimates suggesting an increase from over 18 million cases in 2018 to approximately 29 million by 2040, driven by factors such as population growth and ageing [2]. The most prevalent types of cancer include breast, lung, colorectal, and prostate cancers, with disparities in incidence and mortality rates observed across different regions, particularly between high-income and low-to-middle-income countries [1, 3]. This escalating burden necessitates a deeper understanding of the mechanisms underlying cancer development and progression.

Central to the understanding of both normal tissue homeostasis and cancer pathology is the concept of stem cells. Stem cells are unique cells capable of self-renewal and differentiation into various specialised cell types, playing a crucial role in maintaining healthy tissues. They are essential for tissue repair and regeneration, ensuring that cellular turnover and function are preserved throughout an organism's life. However, the properties that make stem cells vital for normal physiology can also contribute to the pathology of cancer.

Within the tumour microenvironment, a distinct subpopulation of cells known as cancer stem cells (CSCs) has garnered significant attention. CSCs possess stem-like properties, including the ability to self-renew and differentiate, which allows them to drive tumour initiation, progression, and metastasis.

These cells are often resistant to conventional therapies, leading to treatment failure and relapse, which underscores their importance in cancer biology. The existence of CSCs challenges traditional views of

tumour heterogeneity and suggests that targeting these cells may be critical for effective cancer treatment.



Figure 2: Models of CSC-driven tumour heterogeneity.[16] CSC=cancer stem cell.

Source: Cancer stem cells: Role in tumour growth, recurrence, metastasis, and treatment resistance Medicine95(1S): S20-S25, September 2016.

The research question guiding this exploration is: *How do cancer stem cells contribute to tumour initiation, progression, and metastasis?* Understanding the role of CSCs in these processes is essential for developing targeted therapies that can effectively combat cancer and improve patient outcomes. By elucidating the mechanisms through which CSCs operate, researchers hope to identify novel therapeutic strategies that can disrupt their function and ultimately reduce the burden of cancer on global health.

Literature Review:

Cancer stem cells (CSCs) represent a distinct subpopulation of cells within tumours that exhibit properties similar to normal stem cells, including the ability to self-renew and differentiate into various cell types. These cells are believed to play a crucial role in tumour initiation, progression, and metastasis. The origin of CSCs remains a subject of ongoing debate, with current research suggesting three possible sources: normal stem cells, adult progenitor cells, and fusion cells. CSCs can be found in various tissues, including the breast, brain, lung, liver, ovary, and testis, indicating their widespread involvement in different cancer types.

CSCs are characterised by their unique properties, which include self-renewal and differentiation capabilities that contribute to tumour heterogeneity. These properties enable CSCs to maintain long-lived populations within tumours, allowing for excessive self-renewal and tumour formation. The regulation of these properties is mediated by several intracellular signalling pathways, such as Wnt/β-catenin, Notch, transforming growth factor-β (TGF-β), and Hedgehog signalling. These pathways are crucial for maintaining the stem-like characteristics of CSCs and influencing their behaviour within the tumour microenvironment.

To identify CSCs, researchers utilise specific surface markers, including CD24, CD44, CD133, and CD110. For instance, CD133 has been shown to confer cancer stem-like properties by stabilising EGFR-AKT signalling in hepatocellular carcinoma, while CD24 signalling through macrophage Siglec-10 has emerged as a target for cancer immunotherapy. The identification of these markers is essential for isolating CSC populations for further study and for developing targeted therapeutic strategies.

CSCs are integral to tumour initiation due to their inherent abilities to self-renew and differentiate. They can initiate tumour formation by reconstituting cancer cells and generating heterogeneous tumour populations. Evidence supporting the role of CSCs in tumour initiation includes studies demonstrating that distinct populations of CSCs determine tumour growth and metastatic activity, particularly in human pancreatic cancer. Additionally, a subpopulation of CD24+ cells in colon cancer cell lines has been identified as possessing stem cell characteristics capable of initiating tumour formation.

In terms of tumour progression, CSCs contribute significantly to tumour growth and development. Their self-renewal and differentiation abilities allow them to generate various cell types within the tumour, leading to increased heterogeneity. CSCs promote tumour progression through multiple mechanisms, including the dysregulation of key signalling pathways and interactions within the tumour microenvironment. Their resistance to conventional therapeutic strategies also plays a critical role in tumour recurrence and metastasis.

The ability of CSCs to lead to the spread of cancer to other organs is another critical aspect of their biology. CSCs can migrate and invade other tissues, facilitating metastasis due to their self-renewal and differentiation capabilities. The properties that enable CSCs to metastasize include their ability to evade immune attacks through mechanisms such as the downregulation of MHC-I and natural killer ligands, as well as the upregulation of immune checkpoint proteins. This immune evasion, combined with their inherent tumorigenic potential, underscores the importance of targeting CSCs in cancer treatment to improve patient outcomes and reduce the risk of metastasis.

CSCs are typically found to constitute a minor subpopulation within tumours, often ranging from 1% to 5% of the total tumour cell population in various cancers. However, this percentage can increase significantly in advanced or aggressive tumours, where CSCs may represent a larger fraction of the tumour mass. For instance, in some studies, the CSC population in metastatic tumours has been reported to be enriched compared to primary tumours, suggesting that the dynamics of CSCs change as tumours progress and spread.

Data:

Cancer stem cells (CSCs) play a crucial role in tumour initiation, progression, and metastasis. CSCs typically constitute a small percentage of the total tumour cell population, ranging from 0.01-2% of the tumour mass [11, 15]. In breast cancer, CSCs account for approximately 0.1-1% of primary tumour cells [12]. These cells possess unique properties that contribute to cancer development and spread. CSCs have self-renewal ability, tumour-initiating capacity, and can give rise to more differentiated progeny [11]. Compared to non-CSCs, cancer stem cells generally exhibit enhanced proliferation, migration, and resistance to conventional

therapies [13]. CSCs are often enriched in advanced and aggressive tumours, and cells isolated from distant metastases frequently display CSC phenotypes [1]. For instance, in pancreatic cancer, a specific subset of metastasis-capable CSCs (mCSCs) with a CD133+CXCR4+ phenotype has been identified [11]. CSCs also promote angiogenesis and adapt to the tumour microenvironment, further supporting tumour growth and progression 13]. Additionally, CSCs have been implicated in therapy resistance, with residual tumours after conventional treatments often showing an enrichment of CSCs [11]. This resistance contributes to tumour recurrence and metastasis, making CSCs a critical target for developing more effective cancer therapies [13, 15].

Results:

Cancer stem cells (CSCs) are important for how tumours start, grow, and spread. They make up a small part of the tumour, usually between 0.01% and 2%, with breast cancer having about 0.1% to 1% of these cells. CSCs are better at growing, moving, and surviving treatments compared to regular cancer cells. For example, in pancreatic cancer, certain CSCs can lead to metastasis. These cells also help create new blood vessels and adjust to their surroundings, which helps the tumour grow. After treatment, tumours often have more CSCs, which can lead to the cancer coming back. This makes CSCs a key focus for new cancer treatments.

Discussion:

Cancer stem cells (CSCs) are a critical subpopulation of tumour cells that significantly impact our understanding of cancer development and metastasis. These cells, which constitute a small fraction of the tumour, possess unique abilities to self-renew, differentiate, and resist conventional therapies, thereby driving tumour initiation, growth, and recurrence [16, 17, 18]. Understanding CSCs elucidates the mechanisms behind tumour heterogeneity and the ability of tumours to adapt and survive under therapeutic pressure, highlighting the need for targeted treatments that specifically address these resilient cells [19][20]. Current research indicates that targeting CSCs could lead to more effective cancer treatments by preventing relapse and metastasis, as these cells are often responsible for the resurgence of the disease post-therapy [19]. However, our knowledge about CSCs is still limited, particularly regarding their exact origins, the full spectrum of their biomarkers, and the mechanisms underlying their plasticity and resistance to treatment [16][17]. Further research is needed to explore the molecular pathways that regulate CSCs, develop reliable biomarkers for their detection, and design therapies that can selectively target these cells without harming normal stem cells [16, 18, 20].

Conclusion:

Cancer stem cells (CSCs) play a crucial role in understanding cancer initiation, progression, and metastasis. These cells, comprising a small fraction of the tumour (typically 0.01% to 2%), possess unique properties that make them central to cancer biology. CSCs demonstrate enhanced capabilities for growth, migration, and treatment resistance compared to regular cancer cells, contributing significantly to tumour development and spread.

The importance of CSCs in cancer biology cannot be overstated:

1. Tumour initiation and growth: CSCs are key drivers in tumour formation and expansion due to their self-renewal and differentiation abilities.

2. Metastasis: Certain CSCs, such as those in pancreatic cancer, have been linked to the metastatic process, highlighting their role in cancer spread.

3. Treatment resistance: CSCs often survive conventional therapies, leading to an increased proportion of these cells post-treatment and contributing to cancer recurrence.

4. Tumour microenvironment: CSCs contribute to angiogenesis and adapt to their surroundings, facilitating tumour growth.

The potential of CSC research for developing new cancer therapies is significant. By targeting CSCs specifically, future treatments could potentially prevent tumour recurrence and metastasis, addressing major challenges in current cancer management. This approach could lead to more effective and long-lasting cancer treatments, potentially improving patient outcomes and survival rates. Understanding CSCs is reshaping our comprehension of cancer biology and opening new avenues for therapeutic interventions. As research in this field progresses, it holds promise for revolutionising cancer treatment strategies and improving the overall effectiveness of cancer care.

Limitations:

Cancer stem cells (CSCs) present significant challenges in cancer research due to their rarity, heterogeneity, and the limited understanding of their mechanisms. Isolating and studying CSCs is particularly difficult because they constitute a small fraction of the tumour cell population, making their identification and extraction complex and resource-intensive. Furthermore, CSCs exhibit considerable heterogeneity across different tumour types, and even within the same tumour, they can vary in their genetic, epigenetic, and phenotypic characteristics. This diversity complicates the development of universal therapeutic strategies targeting CSCs. Additionally, the specific mechanisms by which CSCs maintain their stemness, contribute to tumour initiation, progression, metastasis, and resistance to conventional therapies are not yet fully elucidated. This limited understanding hampers the ability to effectively target CSCs and necessitates further research to unravel the intricate biology of these elusive

cells.

Future Directions:

Recent advancements in cancer stem cell (CSC) research have focused on developing more effective methods for identifying and isolating these elusive cells. Researchers are exploring combinations of surface markers, functional assays, and advanced technologies like single-cell sequencing to better characterise and isolate CSCs from heterogeneous tumour populations[21, 22]. Concurrently, there is an increased emphasis on investigating the complex signalling pathways that regulate CSC self-renewal and differentiation, with particular attention to pathways such as Notch, Wnt, and Hedgehog[23]. Understanding these molecular mechanisms is crucial for developing targeted therapeutic strategies. As a

result, new approaches are being designed to specifically target CSCs, including the development of drugs that disrupt CSC-specific signalling pathways, inhibit CSC metabolism, or exploit CSC surface markers for targeted delivery of cytotoxic agents [24]. These efforts aim to overcome the limitations of conventional therapies and address the challenges posed by CSCs in cancer recurrence and metastasis.

Citations:

[1] Ferlay, J. "Cancer." *World Health Organization*, World Health Organization, 2022, www.who.int/news-room/fact-sheets/detail/cancer.

[2] Ferlay, J. "The Burden of Cancer." *The Cancer Atlas*, 2018, canceratlas.cancer.org/the-burden/the-burden-of-cancer/.

[3] American Cancer Society. "The Global Cancer Burden." *American Cancer Society*, 2022, www.cancer.org/about-us/our-global-health-work/global-cancer-burden.html.

[4] PAHO. "Burden of Cancer." *PAHO/WHO | Pan American Health Organization*, 2020, www.paho.org/en/enlace/burden-cancer.

[5] Bray, Freddie. "The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control." *Cancer: Disease Control Priorities, Third Edition (Volume 3).*, U.S. National Library of Medicine, 1 Nov. 2015, www.ncbi.nlm.nih.gov/books/NBK343643/.

[6] Ahmad A, et al. "Overview of Cancer Stem Cells (Cscs) and Mechanisms of Their Regulation: Implications for Cancer Therapy." *Current Protocols in Pharmacology*, U.S. National Library of Medicine, 2013, pubmed.ncbi.nlm.nih.gov/23744710/.

[7] Ju, Feng, et al. “Characteristics of the Cancer Stem Cell Niche and Therapeutic Strategies - Stem Cell Research & Therapy.” *BioMed Central*, BioMed Central, 3 June 2022, stemcellres.biomedcentral.com/articles/10.1186/s13287-022-02904-1.

[8] Hanahan, D., et al. “Mechanisms of Cancer Stem Cell Therapy.” *Clinica Chimica Acta*, Elsevier, 11 Aug. 2020, www.sciencedirect.com/science/article/abs/pii/S0009898120303983.

[9] Wikipedia. “Cancer Stem Cell.” *Wikipedia*, Wikimedia Foundation, 11 Aug. 2024, en.wikipedia.org/wiki/Cancer_stem_cell.

[10] Bisht, Shweta, et al. “Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting.” *Stem Cells International*, U.S. National Library of Medicine, 28 June 2022, www.ncbi.nlm.nih.gov/pmc/articles/PMC9256444/.

[11] Suraneni, Mahipal V. “Tumor-Initiating Cells, Cancer Metastasis and Therapeutic Implications.” *Madame Curie Bioscience Database [Internet].*, U.S. National Library of Medicine, 1 Jan. 1970, www.ncbi.nlm.nih.gov/books/NBK169227/.

[12] Chu, Xianjing, et al. “Cancer Stem Cells: Advances in Knowledge and Implications for Cancer Therapy.” *Nature News*, Nature Publishing Group, 5 July 2024, www.nature.com/articles/s41392-024-01851-y.

[13] Ayob, Ain Zubaidah, and Thamil Selvee Ramasamy. “Cancer Stem Cells as Key Drivers of Tumour Progression.” *Journal of Biomedical Science*, U.S. National Library of Medicine, 6 Mar. 2018, www.ncbi.nlm.nih.gov/pmc/articles/PMC5838954/.

[14] Bajaj, Jeevisha, et al. “Stem Cells in Cancer Initiation and Progression | Journal of Cell Biology | Rockefeller University Press.” *Journal of Cell Biology | Rockefeller University Press*, 2019, rupress.org/jcb/article/219/1/e201911053/133538/Stem-cells-in-cancer-initiation-and.

[15] Bao, Bin, et al. “Overview of Cancer Stem Cells (Cscs) and Mechanisms of Their Regulation: Implications for Cancer Therapy.” *Current Protocols in Pharmacology*, U.S. National Library of Medicine, June 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3733496/.

[16] Walcher, Lia, et al. “Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.” *Frontiers*, Frontiers, 20 May 2020, www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01280/full.

[17] Yin, Wen, et al. “Cancer and Stem Cells.” *Experimental Biology and Medicine (Maywood, N.J.)*, U.S. National Library of Medicine, Aug. 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8381702/.

[18] ScienceDirect Topics. “Cancer Stem Cell.” *Cancer Stem Cell - an Overview | ScienceDirect Topics*, www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/cancer-stem-cell. Accessed

18 Aug. 2024.

[19] Yang, Mengqi, et al. “Cancer Stem Cells, Metabolism, and Therapeutic Significance - Tumor Biology.” *SpringerLink*, Springer Netherlands, 10 Feb. 2016, link.springer.com/article/10.1007/s13277-016-4945-x.

[20] Bisht, Shweta, et al. “Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting.” *Stem Cells International*, U.S. National Library of Medicine, 28 June 2022, www.ncbi.nlm.nih.gov/pmc/articles/PMC9256444/.

[21] Duan, Jiang-Jie, et al. “Strategies for Isolating and Enriching Cancer Stem Cells: Well Begun Is Half Done.” *Stem Cells and Development*, U.S. National Library of Medicine, 15 Aug. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3730373/.

[22] Zhang, Xiaoli, et al. “Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond.” *MDPI*, Multidisciplinary Digital Publishing Institute, 14 Dec. 2020, www.mdpi.com/2072-6694/12/12/3765.

[23] Kantara, Carla, et al. “Methods for Detecting Circulating Cancer Stem Cells (Ccscs) as a Novel Approach for Diagnosis of Colon Cancer Relapse/Metastasis.” *Laboratory Investigation; a Journal of Technical Methods and Pathology*, U.S. National Library of Medicine, Jan. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4281282/.

[24] Masciale, Valentina, et al. “Isolation and Identification of Cancer Stem-like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study.” *Frontiers*, Frontiers, 26 Nov. 2019, www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01394/full.

[25] Herreros-Pomares, Alejandro. “Identification, Culture and Targeting of Cancer Stem Cells.” *MDPI*, Multidisciplinary Digital Publishing Institute, 27 Jan. 2022, www.mdpi.com/2075-1729/12/2/184.